Venous Thromboembolism

Publication Title: 
The Journal of Cardiovascular Nursing

The formation of blood clots is a significant threat to individuals with limited mobility, whether in the hospital or recovering in an outpatient setting. Prevention of deep vein thrombosis and pulmonary embolism has been found to be cost-effective when compared with treating an existing thrombosis. Despite these positive findings, compliance with the clinical practice guidelines is less than ideal.

Author(s): 
Long, Janet B.
Publication Title: 
Journal of thrombosis and haemostasis: JTH

BACKGROUND: Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients undergoing major orthopedic surgery (MOS). However, rivaroxaban has never been directly compared with fondaparinux (F), which also shows superior efficacy over enoxaparin. The clinical impact of switching from fondaparinux to rivaroxaban thromboprophylaxis is unclear. OBJECTIVES: To evaluate the efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in unselected patients undergoing MOS.

Author(s): 
Beyer-Westendorf, J.
L¸tzner, J.
Donath, L.
Radke, O. C.
Kuhlisch, E.
Hartmann, A.
Weiss, N.
Werth, S.
Publication Title: 
Theoretical Biology & Medical Modelling

BACKGROUND: Both prophylaxis and treatment of venous thromboembolism (VTE: deep venous thrombosis (DVT) and pulmonary emboli (PE)) with anticoagulants are associated with significant risks of major and fatal hemorrhage. Anticoagulation treatment of VTE has been the standard of care in the USA since before 1962 when the U.S. Food and Drug Administration began requiring randomized controlled clinical trials (RCTs) showing efficacy, so efficacy trials were never required for FDA approval.

Author(s): 
Cundiff, David K.
Agutter, Paul S.
Malone, P. Colm
Pezzullo, John C.
Subscribe to RSS - Venous Thromboembolism